Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if ...

Infrastructure and agriculture equipment manufacturer Valmont Industries (NYSE:VMI) in Q1 CY2025, with sales flat year on ...

IN a letter published in NATURE of February 20, p. 264, Messrs. Uhlenbeck and Goudsmit have shown how great difficulties which atomic theory had met in the attempt to explain spectral structure ...

2-Year U.S. Treasury Note Continuous Contract $103.680 0.172 0.17% 5-Year U.S. Treasury Note Continuous Contract $108.164 0.484 0.45% 10-Year U.S. Treasury Note Continuous Contract $111.094 0.766 ...

Meanwhile, Canaccord Genuity maintained its Hold rating with a $424 target after Vertex announced that its VX-264 program for Type 1 Diabetes would not proceed due to underwhelming clinical trial ...

it bypassed the traditional budget process, which would have included earmarks, now called community project funds, amounting to about $264 million destined for Pennsylvania for the 2025 fiscal year.

Meanwhile, Canaccord Genuity maintained its Hold rating with a $424 target after Vertex announced that its VX-264 program for Type 1 Diabetes would not proceed due to underwhelming clinical trial ...

and VX-264, which are being developed in separate studies for the treatment of type 1 diabetes (T1D). Zimislecel is designed for the transplantation of islet cells alone, using immunosuppression ...

Vertex Pharmaceuticals Incorporated VRTX announced updates on its two novel investigational candidates, zimislecel (formerly VX-880) and VX-264, which are being developed in separate studies for the ...

Vertex Pharmaceuticals is throwing in the towel on its investigational type 1 diabetes islet cell-device combination VX-264 after it failed to increase C-peptide in a 90-day study. Combination ...